

Professional Provider Report

A newsletter for professional providers and their staff members

July 2023 • S-2-23

What's Inside

Coming Soon: Annual CAP Publication	1
Secured emails to Provider Network Services	2
Reminder FREE CEUs offered	2
QBRP Scorecards Reinstated	2
Billing Admin of a Drug Reminder	3
New Biosimilars added	3

Coming Soon: Annual CAP Publication

The 2024 Competitive Allowance Program (CAP) changes and annual reports are coming soon. Please be on the lookout for notification, sent to your email address registered with us, mid-late July that the documents have been published to bcbsks.com.

These materials are sent electronically, if you haven't already, please follow the steps below to sign up for electronic communications:

- Go to bcbsks.com
- Click Providers
- Choose Professional Provider
- Click e-News
- Enter a valid email address, along with a name, billing NPI, facility or organization name, city, and state

To view current and past CAP changes and annual reports please visit, https://www.bcbsks.com/providers/professional/publications/policy-memos.

For more information regarding the annual distribution of CAP materials, contact your professional relations representative or Provider Network Services in Topeka at 785-291-4135 or 800-432-3587.

The Professional Provider Report is published by the Professional Relations department of Blue Cross and Blue Shield of Kansas.

Sarah Shaw, Communications Coordinator



bcbsks.com



Secured emails to Provider Network Services

We would like to encourage provider groups to not send secure emails to our prof.relations@bcbsks. com inbox. Secured emails are not received at this inbox. We are bound by PHI and HIPAA regulations and can ensure we will receive and treat your forms and information sent to us correctly without requiring secured password-protected intake.

If you have any questions or issues with sending emails to our provider network services department, please contact your professional provider representative.

Reminder: FREE CEUs offered

Blue Cross and Blue Shield of Kansas (BCBSKS) would like to remind you that throughout the year, we offer several workshops that provide free Continuing Education Units (CEUs). You can find information regarding our workshops and education opportunities throughout the year on our <u>Education and Workshop page</u> for professional providers.

We also occasionally notify you of additional opportunities for free CEUs, such as NCQA's antibiotic-focused courses that are available on-demand for free. For additional information regarding NCQA's antibiotic-focused courses, see our article in our <u>S-1-23 newsletter</u>.

QBRP Scorecards Reinstated

Blue Cross and Blue Shield of Kansas (BCBSKS) is pleased to announce that the QBRP scorecards have been reinstated within the provider secure section (BlueAccess) of Availity. BCBSKS is committed to ensuring we provide accurate information and have worked diligently to reinstate the QBRP scorecards. We appreciate your patience as we worked to resolve this issue.

BCBSKS had previously noticed an error while displaying the QBRP scorecard in BlueAccess. There were inconsistencies between our reports and what

the scorecard was reflecting. Please be assured the system used to calculate QBRP incentives has always been correct, only the online scorecard was showing inconsistencies.

If you have any questions related to this notice, please contact your professional provider representative.

Page 2 S-2-23 • July 2023



Billing Administration of a Drug Reminder

To determine coverage of a drug and/or vaccine administration code, BCBSKS needs to determine that the drug being administered is a covered benefit. When an administration code is charged without the drug/vaccine being billed, the name or code for the drug can

be documented on the claim by billing a line with the drug code and a \$0.00 charge or by putting the name of the drug in box 19 (Loop 2300 DTP electronically). This will help ensure quick and accurate claims processing for your claims.



New Biosimilars added

On 7/1/2023, new biosimilars for Humira (adalimumab) will be added to Blue Cross and Blue Shield (BCBSKS)'s Select, BlueCare/EPO, and ResultsRx formularies.

There will be no changes in coverage of Humira products. Coverage of additional biosimilars will include Amjevita and Hadlima. You can identify preferred products on MyPrime.com after 7/1/2023. Because there are no clinically meaningful differences between

Humira and the biosimilar adalimumab products, patients are not expected to experience a change in the safety or effectiveness of their treatment if members utilize covered adalimumab biosimilars.¹

If you have any questions related to this notice, please contact your professional provider representative.

1. https://www.fda.gov/files/drugs/published/Biological-Product-Definitions.pdf

July 2023 • S-2-23 Page 3